Roseola natural history, complications and prognosis

Roseola Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Roseola from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Roseola natural history, complications and prognosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Roseola natural history, complications and prognosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Roseola natural history, complications and prognosis
CDC on Roseola natural history, complications and prognosis
Roseola natural history, complications and prognosis in the news
Blogs on Roseola natural history, complications and prognosis
Directions to Hospitals Treating Type chapter name here
Risk calculators and risk factors for Roseola natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Natural history, complications and prognosis

Natural history

HHV-6 infection is usually acquired early in life, between 6 months and 2 years of age, following the loss of protective maternal antibodies. Primary infection can also happen in adults. HHV 6 infection has 3 phases: first is represented by acute primary infection in infants. The second occurs in healthy children and adults; the virus replicates in the salivary glands and is secreted in saliva (for HHV-6B) without inducing any obvious pathology, remains latent at least in lymphocytes and monocytes, and persists in various tissues, possibly with a low-level replication. The third stage occurs infrequently, typically in immunocompromised persons, and is linked to reactivation of virus from latency or reinfection.